Diamedica Therapeutics (DMAC) Price & Analysis

Compare

543 Followers

DMAC Stock Chart & Stats

$6.88

-$0.24(-4.23%)

At close: Jan 08 4:00 PM EST

$6.88

-$0.24(-4.23%)

Day’s Range― - ―

52-Week Range$3.19 - $7.49

Previous CloseN/A

Volume70.76K

Average Volume (3M)311.09K

Market Cap

$355.62M

Enterprise Value$137.79M

Total Cash (Recent Filing)$30.04M

Total Debt (Recent Filing)$292.00K

Price to Earnings (P/E)―

Beta1.58

Next Earnings

Nov 05, 2025

EPS Estimate

-0.16

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.18

Shares Outstanding51,688,910

10 Day Avg. Volume297,114

30 Day Avg. Volume311,093

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.39

Enterprise Value/Revenue9.98

Enterprise Value/Gross Profit19.68K

Enterprise Value/Ebitda-4.43

Forecast

1Y Price Target

$12.00

Price Target Upside74.42% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

Bulls Say, Bears Say

Bulls Say

Clinical Trial ResultsThe announcement of positive interim results from the Phase 2 preeclampsia study of DM199 showed statistically significant and clinically meaningful reductions in blood pressure, indicating potential therapeutic benefits.

Program De-RiskingThe interim Phase 2 update has helped to de-risk the preeclampsia program, increasing confidence in the continuation of the trial.

Safety ProfileNo demonstrated placental transfer across all cohorts and no early labor inductions indicate critical safety for DM199, enhancing its profile for treating preeclampsia.

Bears Say

Clinical Trial RisksDespite positive interim results, further stages of the trial may still present unforeseen challenges or risks.

Diamedica Therapeutics News

ReMEDy2 Trial: A Potential Game-Changer for Acute Ischemic Stroke Treatment

Diamedica Therapeutics (($DMAC)) announced an update on their ongoing clinical study. Study Overview: The ReMEDy2 Trial, officially titled...

8h ago

DMAC

DiaMedica Therapeutics’ Earnings Call Highlights Progress and Challenges

Diamedica Therapeutics (($DMAC)) has held its Q2 earnings call. Read on for the main highlights of the call....

2M ago

DMAC

Buy Rating for Diamedica Therapeutics Driven by Promising Phase 2 Results of DM199 in Preeclampsia

H.C. Wainwright analyst Matthew Caufield reiterated a Buy rating on Diamedica Therapeutics today and set a price target...

2M ago

DMAC

DiaMedica Therapeutics Advances with Positive Trials and Funding

Diamedica Therapeutics ( ($DMAC) ) has released its Q2 earnings. Here is a breakdown of the information Diamedica...

3M ago

DMAC

DiaMedica Therapeutics Enters Sales Agreement with TD Securities

Diamedica Therapeutics ( ($DMAC) ) just unveiled an announcement. On August 12, 2025, DiaMedica Therapeutics Inc. entered into...

3M ago

DMAC

DiaMedica Therapeutics files $100M mixed securities shelf

17:11 EDT DiaMedica Therapeutics (DMAC) files $100M mixed securities shelf Published first on TheFly – the ultimate source...

3M ago

DMAC

DiaMedica Therapeutics reports Q2 EPS (18c), consensus (19c)

“With the recent positive interim results from Part 1a of our Phase 2 study evaluating DM199 in preeclampsia...

3M ago

DMAC

DMAC Earnings Report this Week: Is It a Buy, Ahead of Earnings?

Diamedica Therapeutics (DMAC) is scheduled to report 2nd quarter earnings on 08/12/2025, after the market closes. Regarding Q2...

3M ago

DMAC

DiaMedica Therapeutics CMO Lorianne Masuoka resigns, Julie Krop succeeds

DiaMedica Therapeutics (DMAC) announced the appointment of Julie Krop as chief medical officer, effective immediately. Krop will succeed...

3M ago

DMAC

PRTC

DiaMedica Appoints New Chief Medical Officer

Diamedica Therapeutics ( ($DMAC) ) just unveiled an update. On August 4, 2025, Lorianne Masuoka resigned as Chief...

3M ago

DMAC

DiaMedica Therapeutics files to sell 8.61M common shares for holders

08:32 EDT DiaMedica Therapeutics (DMAC) files to sell 8.61M common shares for holders Published first on TheFly –...

3M ago

DMAC

ReMEDy2 Trial: A New Hope for Acute Ischemic Stroke Treatment?

Diamedica Therapeutics (($DMAC)) announced an update on their ongoing clinical study. The ReMEDy2 Trial, officially titled ‘Phase 2/3...

3M ago

DMAC

DiaMedica Therapeutics Secures $30.1 Million in Private Placement

Diamedica Therapeutics ( ($DMAC) ) has issued an announcement. DiaMedica Therapeutics has successfully closed a $30.1 million private...

3M ago

DMAC

DiaMedica Therapeutics to sell 8.606M shares at $3.50 in private placement

DiaMedica Therapeutics (DMAC) announced definitive agreements for a $30.1M private placement of common shares led by current investors....

3M ago

DMAC

DMAC FAQ

What was Diamedica Therapeutics Inc’s price range in the past 12 months?

Diamedica Therapeutics Inc lowest stock price was $3.19 and its highest was $7.49 in the past 12 months.

What is Diamedica Therapeutics Inc’s market cap?

Diamedica Therapeutics Inc’s market cap is $355.62M.

When is Diamedica Therapeutics Inc’s upcoming earnings report date?

Diamedica Therapeutics Inc’s upcoming earnings report date is Nov 05, 2025 which is in 8 days.

How were Diamedica Therapeutics Inc’s earnings last quarter?

Diamedica Therapeutics Inc released its earnings results on Aug 12, 2025. The company reported -$0.18 earnings per share for the quarter, beating the consensus estimate of -$0.19 by $0.01.

Is Diamedica Therapeutics Inc overvalued?

According to Wall Street analysts Diamedica Therapeutics Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Diamedica Therapeutics Inc pay dividends?

Diamedica Therapeutics Inc does not currently pay dividends.

What is Diamedica Therapeutics Inc’s EPS estimate?

Diamedica Therapeutics Inc’s EPS estimate is -0.16.

How many shares outstanding does Diamedica Therapeutics Inc have?

Diamedica Therapeutics Inc has 51,688,910 shares outstanding.

What happened to Diamedica Therapeutics Inc’s price movement after its last earnings report?

Diamedica Therapeutics Inc reported an EPS of -$0.18 in its last earnings report, beating expectations of -$0.19. Following the earnings report the stock price went up 14.943%.

Which hedge fund is a major shareholder of Diamedica Therapeutics Inc?

Currently, no hedge funds are holding shares in DMAC

Diamedica Therapeutics Stock Smart Score

Outperform

Fundamentals

Return on Equity

-73.41%

Trailing 12-Months

Asset Growth

-44.59%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Diamedica Therapeutics Inc

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Diamedica Therapeutics (DMAC) Earnings & Revenues

Historic Earnings Reports

DMAC Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Neutral

The earnings call highlighted significant progress in DiaMedica's ongoing clinical programs, particularly in preeclampsia and stroke, alongside successful capital raising and strategic additions to the team and market indices. However, the company faces financial challenges with increased net losses and rising operational expenses.View all DMAC earnings summaries

DMAC Stock 12 Month Forecast

Average Price Target

$12.00

▲(74.42% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","4":"$4","7":"$7","10":"$10","13":"$13"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$12.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$12.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$12.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,4,7,10,13],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.32,5.833846153846154,6.3476923076923075,6.861538461538462,7.375384615384616,7.889230769230769,8.403076923076924,8.916923076923077,9.430769230769231,9.944615384615386,10.458461538461538,10.972307692307693,11.486153846153847,{"y":12,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.32,5.833846153846154,6.3476923076923075,6.861538461538462,7.375384615384616,7.889230769230769,8.403076923076924,8.916923076923077,9.430769230769231,9.944615384615386,10.458461538461538,10.972307692307693,11.486153846153847,{"y":12,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.32,5.833846153846154,6.3476923076923075,6.861538461538462,7.375384615384616,7.889230769230769,8.403076923076924,8.916923076923077,9.430769230769231,9.944615384615386,10.458461538461538,10.972307692307693,11.486153846153847,{"y":12,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.95,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.45,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.23,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.25,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.34,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.43,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.76,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.53,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.75,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.13,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.57,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.12,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.32,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >